Skip to content

Staar Surgical STAA US — PP&E (Net)

Other geography segments

CH
$17.31M

Similar metrics at other companies

Alphatec Holdings logo
ATECUS — PP&E (Net)
$136.84M-5.7%
Merit Medical Systems logo
MMSIUS — PP&E (Net)
$300.59M+10.6%
Herbalife logo
HLFUS — PP&E (Net)
$399.7M-2.5%
Payoneer Global Inc. logo
PAYOUS — PP&E (Net)
$2.7M-2.0%
Impinj, Inc. logo
PIUS — PP&E (Net)
$13.39M+1.0%
TripAdvisor logo
TRIPUS — PP&E (Net)
$136M-5.6%

Other financials

Income statement

See full
Revenue$93.5M+120%
Gross profit$68.9M+146%
Operating income$8.0M+114%
Net income$5.2M+110%
EPS (diluted)$0.10+109%

Balance sheet

See full
Cash & equivalents$131.9M-23.8%
Total debt$37.3M+1.7%
Total equity$352.4M+0.7%
Total assets$451.1M-1.4%

Cash flow

See full
Operating cash flow-$21.7M-278%
CapEx$443.0K-69.8%
Free cash flow-$22.1M-207%

Valuation

See full
Market cap$1.44B+77.9%
Enterprise value$1.35B+100.0%
P/S+2.1×

Profitability

See full
Gross margin76.9%+2.9pp
Operating margin-9.1%-3.5pp
Net margin-7.2%-3.0pp
FCF margin-19.6%+55.9pp

Returns & leverage

See full
Return on equity-6%-2.4pp
Debt / equity0.1×0.0×
Current ratio5.1×+0.3×

Where this comes from

Reported directly by Staar Surgical in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Staar Surgical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Staar Surgical's us — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Staar Surgical's US — PP&E (net)?
Staar Surgical (STAA) reported US — PP&E (net) of $54.17M in Q1 2026.
How has Staar Surgical's US — PP&E (net) changed year-over-year?
Staar Surgical's US — PP&E (net) decreased by 6.7% year-over-year, from $58.03M to $54.17M.
What does US — PP&E (net) mean?
Represents the net book value of tangible long-term assets located within the United States used in the production and distribution of ophthalmic lenses. This metric reflects the company's investment in manufacturing infrastructure and facilities necessary to support domestic operations. It is a key indicator of the capital intensity required to maintain the company's US-based production capabilities.